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Abstract
The prime objective of the present multicenter, prospective study was to evaluate the suitability of sentinel
lymph node biopsy for patients with node-positive breast cancer before neoadjuvant chemotherapy. The
present study enrolled 143 patients with breast cancer with positive axillary nodes at the initial diagnosis.
Sentinel lymph node biopsy after neoadjuvant chemotherapy in these patients was technically feasible but
should not be recommended for the luminal subtype.
Background: Sentinel lymph node biopsy (SNB) is the standard treatment of node-negative breast cancer; however,
whether SNB should be performed for patients with node-positive disease before neoadjuvant chemotherapy (NAC) is
controversial. We evaluated the accuracy of SNB after NAC in patients with breast cancer with nodal metastasis before
chemotherapy to determine the false-negative rate (FNR) and detection rate for SNB. Patients and Methods: In the
present multicenter prospective study performed from September 2011 to April 2013, 143 patients with breast cancer
and positive axillary nodes, proved by ﬁne needle aspiration cytology at the initial diagnosis (stage T1-T3N1M0), were
enrolled. All patients underwent breast surgery with SNB and complete axillary lymph node dissection. Results: After
NAC, the pathologic complete nodal response rate was 52.4%. The sentinel lymph node could be identiﬁed in 130 cases
(90.9%); the FNR was 16.0% (13 of 81). The FNR of each clinical subtype was 42.1% (8 of 19) for the estrogen receptor-
positive and human epithelial growth factor 2 (HER2)-negative (luminal type), 16.7% (2 of 12) for ER-positive and HER2-
positive (luminal-HER2 type), 3.2% (1 of 31) for HER2-positive (HER2-enriched type), and 10.5% (2 of 19) for ER-negative
and HER2-negative (triple-negative breast cancer; P ¼ .003). The FNR was signiﬁcantly greater in the luminal than in the
nonluminal type (odds ratio, 9.91; 95% conﬁdence interval, 6.77-14.52). Conclusion: SNB after NAC in patients with
initially node-positive breast cancer was technically feasible but should not be recommended for the luminal subtype.
However, the tumor subtype can guide patient selection, and axillary lymph node dissection could be omitted for the
luminal-HER2, HER2-enriched, and triple-negative breast cancer subtypes.
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SNB After NAC for Initial Diagnosis of Node-positive Breast CancerIntroduction dye and radiolabeled colloid agents was recommended to maximize
Axillary lymph node status is important both as a prognostic
factor in breast cancer1-3 and as a factor determining treatment.
Previously, axillary lymph node dissection (ALND) was performed
to conﬁrm the axillary lymph node status; however, this resulted in
postoperative complications such as lymphedema and/or motor
deﬁcits in many cases.4-6 Therefore, sentinel lymph node biopsy
(SNB) was established to evaluate the lymph nodes, and it has
recently become a standard treatment for clinically node-negative
breast cancer, leading to a comparative decrease in the occurrence
of postoperative complications.
Neoadjuvant chemotherapy (NAC) is a common treatment used
for patients with locally advanced and lymph node-positive breast
cancer to reduce the tumor size, increase the rate of breast-
conserving surgery, and acquire information regarding chemo-
therapy sensitivity. The use of SNB after NAC is controversial. A
meta-analysis of studies in which SNB was performed after NAC in
patients with clinically node-negative cancer showed acceptable
accuracy.7 Nevertheless, ALND remains the standard surgical
treatment of node-positive disease; however, negative conversion of
lymph node metastasis due to chemotherapy has been reported in
approximately 40% of cases.8,9 ALND is unnecessary in such cases,
and the associated postoperative complications can be avoided if the
axillary lymph node status can be accurately evaluated by SNB.
The present clinical trial was designed to determine the accuracy
of SNB after NAC in patients who had presented with pathologi-
cally conﬁrmed axillary node metastasis before chemotherapy.
Patients and Methods
The present prospective, multicenter study was performed at 8
centers in Japan from September 2011 to April 2013. The inclusion
criteria were (1) women aged  20 years; (2) histologically
conﬁrmed clinical stage T1 through T3N1M0 primary invasive
breast cancer; (3) initially conﬁrmed axillary node metastasis by ﬁne
needle aspiration cytology before NAC; (4) completion of NAC
(the chemotherapy regimen was determined at the discretion of the
treating medical team); (5) tumors negative for lymph node
metastasis conﬁrmed by imaging after NAC; and (6) Eastern
Cooperative Oncology Group performance status of 0 or 1. The
exclusion criteria were a history of bilateral breast cancer, inﬂam-
matory breast cancer, ipsilateral breast cancer recurrence, and pre-
vious SNB. All patients provided written informed consent. A
central ethics committee (Showa University School of Medicine)
reviewed the protocol, and the local ethics committees approved it.
Axillary Lymph Node Evaluation
Physical examination and ultrasonography were performed before
and after NAC to evaluate whether axillary lymph node metastasis
persisted. Node positivity was deﬁned as lymph nodes that were
palpable, those > 1 cm in size, those showing reduced fatty depo-
sition, and those demonstrating lateral cortical hypertrophy on
ultrasonography.
Surgical Intervention
Surgical resection (breast-conserving surgery or mastectomy) was
performed for the primary lesion, and SNB followed by ALND
were performed for all the patients. For SNB, a combination of blueClinical Breast Cancer August 2016the likelihood of sentinel lymph node (SLN) identiﬁcation.
Histopathologic Examination
The primary lesion, axillary lymph node status, and various
biomarkers were evaluated before and after NAC. For the axillary
lymph nodes, data were collected on the number of SLNs, the
number of lymph nodes obtained by ALND (non-SLNs), and
lymph node status. SLNs were deﬁned as positive for metastasis if
residual tumor was observed, regardless of the size. The pathologic
stage was determined using the Union for International Cancer
Control TNM classiﬁcation, 7th edition.
The estrogen receptor (ER), progesterone receptor (PgR), and
human epithelial growth factor 2 (HER2) status of the tumor was
evaluated using immunohistochemical staining of breast specimens
obtained using core needle biopsy. For ER and PgR, the tumor was
considered positive when the ratio of stained cells was > 10% and
the Allred score was 4 to 8, and the tumor was considered negative
when < 10% of the cells were stained and the Allred score was 0 to
3. The staining for HER2 was evaluated using the HercepTest
(Dako, Glostrup, Denmark). The scoring was interpreted as 0 to 3
according to the American Society of Clinical Oncology/College of
American Pathologists guidelines.10 HER2 was considered positive
in cases with immunohistochemistry ﬁndings of 3 or with gene
ampliﬁcation observed on ﬂuorescence in situ hybridization.
On the basis of the ER, PgR, and HER2 ﬁndings, the clinical
tumor subtypes were categorized as follows: luminal type, ER-
positive and/or PgR-positive and HER2-negative; luminal-HER2
type, ER-positive and/or PgR-positive and HER2-positive; HER2-
enriched type, ER-negative, PgR-negative, and HER2-positive;
and triple-negative breast cancer (TNBC), ER-negative, PgR-
negative, and HER2-negative.
Outcomes
The primary endpoint was the false-negative rate (FNR) of SNB
after chemotherapy in patients who were found to have no positive
SLN but had  1 positive non-SLNs. The secondary endpoint was
the identiﬁcation rate of the SLNs.
Statistical Analysis
Univariate analysis was performed using the c2 test and Mann-
Whitney U test to evaluate the relationship between the FNR
and clinical tumor characteristics. Multivariate analysis was per-
formed using a logistic regression model with statistically signiﬁcant
variables on the univariate analyses. Analyses were performed using
the SPSS, version 21.0, statistical software package (SPSS Inc.,
Chicago, IL), with P < .05 considered signiﬁcant.
Results
Patient and Tumor Characteristics
A total of 143 patients were enrolled in the study. The patient
and tumor characteristics are listed in Table 1. The median age of
the patients at surgery was 51 years (range, 30-74 years). All the
cases in the present study were invasive ductal carcinoma. Before
NAC, 20 patients (14.0%) had clinical stage IIA, 95 (66.4%) had
stage IIB, 20 (14%) had stage IIIA, 7 (4.9%) had stage IIIB, and
1 (0.7%) had stage IIIC tumors. The distribution of the clinical
Table 2 Diagnostic Performance of Sentinel Lymph Node
Biopsy After Neoadjuvant Chemotherapy in Patients
With Initially Diagnosed With Node-Positive Disease
Variable n (%)
Lymphatic mapping agent
Blue dye 7 (4.9)
Blue dye and radiolabeled colloid
agents
136 (95.1)
SLN identiﬁcation
Successful 130 (90.9)
Unsuccessful 13 (9.1)
No. of SLNs removed
1 65 (50.0)
2 46 (35.4)
3 19 (14.6)
No. of SLNs with residual metastasis
0 81 (62.3)
1 39 (30.0)
2 8 (6.2)
3 2 (1.6)
No. of SLNs with residual metastasis
0 96 (67.1)
1 25 (17.5)
2 9 (6.3)
3 13 (9.1)
Katsutoshi Enokido et altumor subtypes was as follows: 50 (35%) luminal, 25 (17.5%)
luminal-HER2, 39 (27.3%) HER2-enriched, and 29 (20.3%)
TNBC. After NAC, the primary tumor showed a complete clinical
response in 37 (25.9%), a partial response in 96 (67.1%), and no
response in 10 (7.0%). The pathologic complete response (pCR)
rate of the primary tumors was 37.8%.
Detection of SLNs
Of the 143 patient who underwent SNB lymph node surgery
(Table 2), 7 (4.9%) underwent the procedure with the blue dye
only and 136 (95.1%) with a combination of the blue dye and
radiolabeled colloid agents. SLNs were identiﬁed in 130 patients
(90.9%) and not detected in 13 patients (9.1%). The mean number
of removed lymph nodes was 1.6 in 130 patients with identiﬁed
SLNs. Pathologic examination of the SLNs and non-SLNs removed
on ALND revealed no residual nodal disease in 68 of these patients,
yielding a complete nodal response rate of 47.6%. A total of 81
cases (62.3%) were negative for SLN metastasis, and 49 cases
(37.7%) had  1 positive node. In 13 patients, residual cancer was
not identiﬁed in the SLNs but was found in the non-SLNs,
resulting in an FNR of 16.0% (13 of 81).
The analysis according to the clinical tumor subtype revealed that
the rate of SLN identiﬁcation was 90.0% (45 of 50) in the luminal,
92.0% (23 of 25) in the luminal-HER2, 89.7% (35 of 39) in the
HER2-enriched, and 93.1% (27 of 29) in the TNBC subtypes
(Figure 1). The clinicopathologic factors affecting the FNR are
listed in Table 3. On univariate analysis, the FNR was signiﬁcantlyTable 1 Patient Characteristics (n [ 143)
Characteristic n (%)
Age (years)
Median 51
Range 30-74
Average tumor size (mm) 34.0
Histologic type, invasive ductal
carcinoma
143 (100)
Clinical stage
IIA 20 (14.0)
IIB 95 (66.4)
IIIA 20 (14.0)
IIIB 7 (4.9)
IIIC 1 (0.7)
Response to NAC
CR 37 (25.9)
PR 96 (67.1)
SD 10 (7.0)
Clinical tumor biomarker
Luminal 50 (35.0)
Luminal þ HER2 25 (17.5)
HER2-enriched 39 (27.3)
TNBC 29 (20.3)
Abbreviations: CR ¼ complete response; HER2 ¼ human epidermal growth factor receptor 2;
NAC ¼ neoadjuvant chemotherapy; PR ¼ partial response; SD ¼ stable disease; TNBC ¼
triple-negative breast cancer.
Abbreviation: SLN ¼ sentinel lymph node.lower in the hormone receptor-negative and HER2-positive pa-
tients. According to the clinical tumor subtype, the FNR was 42.1%
(8 of 19) in the luminal, 16.7% (2 of 12) in the luminal-HER2,
3.2% (1 of 31) in the HER2-enriched, and 10.5% (2 of 19) in
the TNBC subtypes (Figure 2), indicating that the FNR was
signiﬁcantly greater in the luminal type than in the nonluminal type
(odds ratio, 9.91; 95% conﬁdence interval, 6.77-14.52; Table 4).
Discussion
SNB for patients with breast cancer was introduced by Krag et al11
in 1993, and its use has subsequently increased rapidly. According to
large clinical trials and meta-analyses, the FNR was 7.3% to 9.7%.12-15
In cases in which the SLN is negative for metastasis, ALND can be
omitted without affecting the prognosis,14,16 and the rate of post-
operative complications is low; therefore, the omission of ALND has
become the standard management in such cases.
NAC was introduced for locally advanced breast cancer in the
1970s. The National Surgical Adjuvant Breast and Bowel Project
B-1817 and B-2718 trials showed no signiﬁcant differences in the
disease-free survival and overall survival between the NAC group
and the adjuvant group. Furthermore, in both these studies, patients
with a pCR had signiﬁcantly superior disease-free survival and
overall survival compared with patients without a pCR. NAC has
become one of the standard treatments of node-positive breast
cancer or large tumors. For patients undergoing NAC, it has been
recommended that SNB be performed before treatment.19 Ac-
cording to a retrospective analysis of NAC in a large clinical trialClinical Breast Cancer August 2016 - 301
Figure 1 Tumor Identiﬁcation Rate According to Clinical
Tumor Biomarkers
Abbreviations: ER ¼ estrogen receptor; HER2 ¼ human epithelial growth factor 2;
TNBC ¼ triple-negative breast cancer.
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SLN identiﬁcation rate in 428 patients receiving SNB was 84.9%,
with an FNR of 10.7%. A meta-analysis (involving 1273 patients
from 21 studies) by Xing et al7 revealed an identiﬁcation rate of
91%, with 88% sensitivity. Hence, they concluded that SNB after
NAC was possible.7 In a systematic review by Kelly et al,20 the
identiﬁcation rate was 89.6%, the FNR was 8.4%, and no signiﬁ-
cant difference in regional recurrence was observed between those
who had undergone NAC and those who had not (0.9% vs. 1.2%,
respectively; P ¼ .5). From these results, it can be concluded that,
with proper care, SNB can be performed in cases without lymph
node metastases before NAC and ALND can be omitted.Table 3 Clinicopathologic Factors Affecting the False-Negative Rat
Clinicopathologic Factor False-Negative Findings (Total)
ER
Positive 10 (50)
Negative 3 (31)
PgR
Positive 8 (24)
Negative 5 (57)
HER2
Positive 3 (43)
Negative 10 (38)
Clinical tumor subtype
Luminal 8 (19)
Luminal þ HER2 2 (12)
HER2-enriched 1 (31)
TNBC 2 (19)
Pathologic response to NAC
pCR 2 (27)
Non-pCR 11 (54)
Abbreviations: CR ¼ complete response; ER ¼ estrogen receptor; FNR ¼ false-negative rate;
pCR ¼ pathologic complete response; PgR ¼ progesterone receptor; TNBC ¼ triple-negative breas
Clinical Breast Cancer August 2016In cases staged as N1 or higher, the omission of lymph node
dissection by SNB is concerning. In 2 clinical trials (American
College of Surgeons Oncology Group [ACOSOG] Z1071 trial
and Sentinel-lymph-node biopsy in patients with breast cancer
before and after neoadjuvant chemotherapy [SENTINA]),21,22
the validity of SNB after NAC in cases of clinically node-
positive breast cancer was assessed. In the ACOSOG Z1071
trial,21 756 patients, including 649 with clinical N1 disease,
were enrolled. Axillary lymph node metastasis was documented
by ﬁne needle aspiration cytology or core needle biopsy. The
identiﬁcation rate of SLNs was 92.9%, and the FNR was 12.6%.
However, the FNR differed according to the number of removed
lymph nodes; the FNR was 31.5% when 1 SLN was removed,
21% when 2 were removed, and 9.1% when  3 nodes were
removed. The SENTINA trial was a large study conducted across
103 institutions in Germany and Austria.22 Women with breast
cancer who were scheduled to receive NAC were enrolled.
Women with initially node-positive disease received NAC, and
those with conversion to clinically node-negative disease after
chemotherapy were treated with SNB followed by ALND. The
SENTINA trial revealed an identiﬁcation rate of 80.1%; the
FNR was 24.3% for women with 1 node removed and 18.5% for
those with 2 SLNs removed. Thus, both studies showed that the
FNR was < 10% only when  3 lymph nodes had been
removed.
In recent years, breast cancers have been classiﬁed into 4 mo-
lecular subtypes according to the combination of hormone receptor
and HER2/neu receptor expression. The sensitivity to chemo-
therapy differs according to the subtype, and subtype diagnosis can
inﬂuence the appropriate management and drug choice in preop-
erative treatment.23 In addition, the subtype is useful for predicting
the risk of axillary lymph node metastasis.24-28e
FNR (%) P Value
.004
20.0
9.7
.016
33.3
8.7
.031
7.0
26.3
.003
42.1
16.7
3.2
10.5
.21
7.4
20.4
HER2 ¼ human epidermal growth factor receptor 2; NAC ¼ neoadjuvant chemotherapy;
t cancer.
Figure 2 False-Negative Rate According to Clinical Tumor
Biomarkers
Abbreviations: ER ¼ estrogen receptor; HER2 ¼ human epithelial growth factor 2;
TNBC ¼ triple-negative breast cancer.
Katsutoshi Enokido et alThe use of preoperative treatment with or without the addition of
trastuzumab therapy for HER2-positive breast cancer has been re-
ported. A randomized trial by Buzdar et al29 showed that a signif-
icant difference in the pCR rate between patients treated with and
without the addition of trastuzumab (65.2% vs. 26.3%, respec-
tively; P ¼ .016). Of the cases enrolled in the present study, 35%
were the luminal type, relatively low compared with the generally
reported percentages (60%-70%), with a tendency toward the use of
NAC, considering the drug sensitivity. In addition, in our study, the
SLN identiﬁcation rate and FNR were shown to vary according to
subtype. The ACOSOG Z1071 trial concluded that it is important
to remove  2 SLNs for minimizing the FNR and that clip
placement could help improve the accuracy of SNB. Our study
showed similar data considering the FNR, although > 80% of the
patients had had < 2 nodes removed. In particular, those with
HER2-enriched and the TNBC subtype had a FNR of  10%.
Although the number of cases examined was limited, the FNR
among those with the luminal subtype was high, making it difﬁcult
to recommend SNB. In contrast, the FNR among the luminal-
HER2, HER2-enriched, and TNBC subtypes was low. Thus, ourTable 4 Multiregression Model for Clinicopathologic Factors
Affecting False-Negative Rate
Variable OR 95% CI P Value
Tumor size after
NAC (mm)
1.04 0.05-21.94 .129
Patient age 1.05 0.08-14.08 .202
Clinical tumor
subtype (luminal
vs. nonluminal)
9.92 6.77-14.52 .002
Pathologic
response to NAC
(pCR vs.
non-pCR)
1.96 1.16-3.31 .436
Abbreviations: CI ¼ conﬁdence interval; NAC ¼ neoadjuvant chemotherapy; OR ¼ odds ratio;
pCR ¼ pathologic complete response.data suggest that it is possible to guide patient selection according to
the clinical tumor subtype.Conclusion
The results of our prospective study do not recommend the
routine use of SNB for evaluating the status of residual axillary
metastasis after NAC in patients with initially diagnosed cytology-
proven node-positive breast cancer. It is preferable to individualize
axillary management after NAC according to the clinical tumor
subtype, and it might be possible to perform SNB in selected pa-
tients (ie, those with the luminal-HER2, HER2-enriched, or
TNBC subtype).
Clinical Practice Points
 SNB and ALND is the standard treatment for node-negative and
node-positive breast cancer, respectively; SNB and ALND are
generally applied during NAC for locally advanced breast cancer.
 It has been seen that approximately 40% of node-positive cancer
will change to node-negative after NAC.
 Hence, in the present study, we evaluated the accuracy of SNB
after NAC in patients with breast cancer presenting with
cytology-proven axillary node metastasis before chemotherapy to
determine the FNR and detection rate for SNB after chemo-
therapy in women initially presenting with cytology-proven
node-positive breast cancer.
 The results of the present study have shown that with proper
care, SNB can be performed in patients without lymph node
metastases before NAC and ALND can be omitted.
 In addition, the present study showed that it might be possible to
perform SNB in selected patients (ie, those with the luminal-
HER2, HER2-enriched, and TNBC subtypes).Acknowledgments
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